How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,101 results for

Refractory Depression Management

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Radically open dialectical behaviour therapy for refractory depression: the RefraMED RCT

Radically open dialectical behaviour therapy for refractory depression: the RefraMED RCT Radically open dialectical behaviour therapy for refractory depression: the RefraMED RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue (...) }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Radically open dialectical behaviour therapy was not significantly better than usual care in reducing depression after 12 months, and had an incremental cost per QALY of about £220,000. {{author}} {{($index , , , , , , , , , , , , , , & . Thomas R Lynch 1, * , Roelie J Hempel 1 , Ben Whalley 2 , Sarah Byford 3 , Rampaul Chamba 4 , Paul Clarke 5 , Susan Clarke 6 , David Kingdon 7 , Heather O’Mahen 8 , Bob Remington 1 , Sophie C Rushbrook 6

2019 NIHR HTA programme

2. Transcranial magnetic resonance-guided focused ultrasound and deep brain stimulation for refractory depression

the Australian community more than $600 million each year in treatment payments, and individuals with treatment- resistant depression contribute a disproportionate amount to the cost. People with depression that does not respond to conventional treatment are frequent users of healthcare services, and treatment costs for refractory depression may be up to 19 times greater than for patients who respond to treatment with medication and psychotherapy. The management of treatment-resistant depression involves (...) of the burden of disease due to depression. Available data, such as those captured through hospital admissions by the Australian h Email sent 28 July 2016; the contact was forwarded to the managing director of MediGroup to respond to Australian enquiries regarding ExAblate. i Brief information about the use of ExAblate is available from the MediGroup website. DBS and tcMRg FUS for refractory depression: December 2016 5 Institute of Health and Welfare, and data on the population living with mental health

2016 COAG Health Council - Horizon Scanning Technology Briefs

3. Refractory Depression Management

Refractory Depression Management Refractory Depression Management Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Refractory (...) Depression Management Refractory Depression Management Aka: Refractory Depression Management , Depression Unresponsive to Medication From Related Chapters II. Management: Step 1 Assess Maximize non-medication therapies (e.g. , psychotherapy) See Assess Adequacy of trial Minimum Duration: 6-8 weeks Minimum Dose: one dose increase at 2-4 weeks Assess for comorbid confounding factors Increased Psychosocial Stressors or Excessive intake Chronic medical illness Assess Compliance Has patient abruptly

2018 FP Notebook

4. Trial of MR-guided Focused Ultrasound for Treatment of Refractory Major Depression

Trial of MR-guided Focused Ultrasound for Treatment of Refractory Major Depression Trial of MR-guided Focused Ultrasound for Treatment of Refractory Major Depression - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Trial of MR-guided Focused Ultrasound for Treatment of Refractory Major Depression The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03421574 Recruitment Status : Recruiting First Posted : February 5, 2018 Last

2018 Clinical Trials

5. A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)

A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD) A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03610048 Recruitment Status : Enrolling by invitation First Posted : August 1, 2018 Last Update Posted : November 28, 2018

2018 Clinical Trials

6. A systematic review of treatments for refractory depression in older people

A systematic review of treatments for refractory depression in older people A systematic review of treatments for refractory depression in older people A systematic review of treatments for refractory depression in older people Cooper C, Katona C, Lyketsos K, Blazer D, Brodaty H, Rabins P, De Mendonca Lima CA, Livingston G CRD summary The authors concluded that there was a paucity of evidence on treatment refractory depression, but half the older people examined responded to additional (...) or alternative pharmacological treatment. Further high-quality research was needed urgently. Given the poor quality of the small evidence base, findings should be interpreted with caution. The recommendations for further high-quality research seem appropriate. Authors' objectives To evaluate the role of pharmacological, physical and psychological interventions for the treatment of refractory depression in older people. Searching PubMed, Web of Science and Cochrane Database of Systematic Reviews were searched

2012 DARE.

7. Guidance on the clinical management of depressive and bipolar disorders, specifically focusing on diagnosis and treatment strategies

Guidance on the clinical management of depressive and bipolar disorders, specifically focusing on diagnosis and treatment strategies First published in Australian and New Zealand Journal of Psychiatry 2015, Vol. 49(12) 1-185. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders Gin S Malhi 1,2 , Darryl Bassett 3,4 , Philip Boyce 5 , Richard Bryant 6 , Paul B Fitzgerald 7 , Kristina Fritz 8 , Malcolm Hopwood 9 , Bill Lyndon 10,11,12 , Roger (...) Linton Meagher, Professor Philip Mitchell, Professor Daniel O’Connor, Dr Nick O’Connor, Dr Tim Outhred, Dr Mark Rowe, Dr Narelle Shadbolt, Dr Martien Snellen, Professor John Tiller, Dr Bill Watkins, Dr Raymond Wu. Keywords Guidelines, depression, bipolar disorder, depressive disorder, mania, mood disorders, management, treatment Introduction Overview. The mood disorders committee (MDC) has been mindful that effective clinical care involves the art of applying clinical knowledge and skills

2015 Royal Australian and New Zealand College of Psychiatrists

8. A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)

A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD) A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03188185 Recruitment Status : Recruiting First Posted : June 15, 2017 Last Update Posted : March

2017 Clinical Trials

9. Axicabtagene ciloleucel (Yescarta) - relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL)

, Cwynarski K, et al. Guidelines for the management of diffuse large B-cell lymphoma. Br J Haematol. 2016;174(1):43-56. Epub 05/20. 7. Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-8. 8. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma (...) Axicabtagene ciloleucel (Yescarta) - relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL) Published 07 October 2019 1 SMC2189 axicabtagene ciloleucel 0.4 – 2 x 10 8 cells dispersion for infusion dispersion for infusion (Yescarta®) Kite Pharma, a Gilead Company 06 September 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees

2019 Scottish Medicines Consortium

10. Clinical Practice Guideline on the Management of Depression in Adults

Clinical Practice Guideline on the Management of Depression in Adults Clinical Practice Guideline on the Management of Depression in Adults CLINICAL PRACTICE GUIDELINES IN THE SPANISH NHS MINISTRY OF HEALTH, SOCIAL SERVICES AND EQUALITYClinical Practice Guideline on the Management of Depression in Adults MINISTERIO DE SANIDAD, SERVICIOS SOCIALES E IGUALDAD MINISTERIO DE ECONOMÍA Y COMPETITIVIDAD CLINICAL PRACTICE GUIDELINES IN THE SPANISH NHS MINISTRY OF HEALTH, SOCIAL SERVICES AND EQUALITYThis (...) , an autonomous body of the Ministry of Economy and Competitiveness, and the Profesor Novoa Santos Foundation, within the activities of the Spanish Network of T echnology and Services Evaluation Agencies for the SNS, financed by the Ministry of Health, Social Services and Equality. This guideline was prepared by: Working Group of the Clinical Practice Guideline on the Management of Depression in Adults. Clinical Practice Guideline on the Management of Depression in Adults. Ministry of Health, Social Services

2015 GuiaSalud

11. ESMO Clinical Practice Guidelines for the Management of Refractory Symptoms at the End of Life and the Use of Palliative Sedation

ESMO Clinical Practice Guidelines for the Management of Refractory Symptoms at the End of Life and the Use of Palliative Sedation ESMOClinicalPracticeGuidelinesforthemanagement ofrefractorysymptomsattheendoflifeandtheuseof palliativesedation † N.I.Cherny 1 ,onbehalfoftheESMOGuidelinesWorkingGroup * 1 DepartmentofMedicalOncology,ShaareZedekMedicalCenter,Jerusalem,Israel Levelofevidencestatement: Since there are no randomised studies addressing this issue, all assertions are level V based on case (...) pain), and it often becomes more dif?cult to achieve adequate relief [19–25]. For some patients, the degree of suffering related to these symptoms may be intolerable. Despite intensi?ed efforts to manage such pro- blems, some patients do not achieve adequate relief and they continue to suffer from inadequately controlled symptoms that maybetermed ‘refractory’. refractorysymptomsattheendoflife Theterm ‘refractory’canbeappliedtosymptomsthatcannotbe adequately controlled despite aggressive efforts

2014 European Society for Medical Oncology

12. Chronic refractory dyspnoea. Evidence based management

depression in opioid-naïve pal- liative care patients during symptomatic therapy of dyspnea with strong opioids? j Palliat Med 2008;11:204–16. 18. Currow DC, Abernethy AP , Frith P . Morphine for management of refractory dyspnoea. bMj 2003;327:1288–9. 19. Ander DS, Aisiku IP , Ratcliff jj, Todd Kh, Gotsch K. Measuring the dyspnea of decompensated heart failure with a visual analog scale: how much improvement is meaningful? Congest heart Fail 2004;10:188–91. 20. Karras Dj, Sammon ME, Terregino CA, lopez (...) Chronic refractory dyspnoea. Evidence based management clinical Background Chronic refractory dyspnoea is defined as breathlessness daily for 3 months at rest or on minimal exertion where contributing causes have been treated maximally. Prevalent aetiologies include chronic obstructive pulmonary disease, heart failure, advanced cancer and interstitial lung diseases. Objective To distil from the peer reviewed literature (literature search and guidelines) evidence that can guide the safe

2013 Clinical Practice Guidelines Portal

13. Refractory Depression, Fatigue, Irritable Bowel Syndrome, and Chronic Pain: A Functional Medicine Case Report (PubMed)

Refractory Depression, Fatigue, Irritable Bowel Syndrome, and Chronic Pain: A Functional Medicine Case Report Single-disorder or single-organ-system clinical practice guidelines are often of limited usefulness in guiding effective management of patients with chronic multidimensional signs and symptoms. The presence of multiple long-standing medical problems in a given patient despite intensive medical effort suggests that addressing systemic core imbalances could complement more narrowly (...) focused approaches.A 72-year-old man experiencing longstanding depression, fatigue, irritable bowel syndrome, and chronic pain in the context of additional refractory illnesses was assessed and treated, guided by a system-oriented approach to underlying core imbalances termed functional medicine. This patient was referred from a team of clinicians representing primary care, cardiology, gastroenterology, hematology, and psychology. Prior treatment had been unsuccessful in managing multiple chronic

Full Text available with Trip Pro

2016 The Permanente journal

14. N-Acetyl Cysteine Supplementation in Therapy Refractory Major Depressive Disorders

N-Acetyl Cysteine Supplementation in Therapy Refractory Major Depressive Disorders N-Acetyl Cysteine Supplementation in Therapy Refractory Major Depressive Disorders - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. N-Acetyl Cysteine Supplementation in Therapy Refractory Major Depressive Disorders The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02972398 Recruitment Status : Recruiting First Posted : November 23, 2016 Last

2016 Clinical Trials

15. Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder

Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02660528 Recruitment Status : Recruiting First Posted : January 21, 2016 Last Update Posted : November

2016 Clinical Trials

16. Vagus Nerve Stimulation for chronic major depressive episodes

in Table 1. Table 2 Proposed MBS item descriptors, as per the ratified PICO Confirmation Category 3 - THERAPEUTIC PROCEDURES Vagus nerve stimulation using an ELECTRICAL PULSE GENERATOR (subcutaneous placement of) to stimulate the left vagus nerve, for management of patients (aged 18 years of age or older) with a chronic major depressive episode who have not had an adequate response to four or more appropriate antidepressant treatments (i.e. at least four medications have been tried for sufficient time (...) to stabilise dose and manage side effects, before an assessment of failure of therapeutic effect is made) Multiple Services Rule (Anaes.) (Assist.) Fee: $340.60 Benefit: 75% = $255.45 (In-hospital/admitted patient only) Category 3 - THERAPEUTIC PROCEDURES Vagus nerve stimulation using an ELECTRICAL PULSE GENERATOR (surgical re-positioning or removal of), for management of patients (aged 18 years of age or older) with a chronic major depressive episode who have not had an adequate response to four or more

2019 Medical Services Advisory Committee

17. Backing into the future: pharmacological approaches to the management of resistant depression. (PubMed)

Backing into the future: pharmacological approaches to the management of resistant depression. Pragmatic studies indicate that a substantial number of depressed patients do not remit with current first-line antidepressant treatments and after two failed treatment steps the chance of remission with subsequent therapies is around 15%. This paper focuses on current evidence for pharmacological treatments in resistant depression as well as possible future developments. For patients who have failed (...) of the pathophysiological role of inflammation in depression offers great opportunities for future treatment in terms of repurposing anti-inflammatory agents from general medicine and pre-treatment stratification of those depressed patients in whom such interventions are likely to be beneficial. Finally an older drug, the dopamine receptor agonist pramipexole, if used carefully may well improve the prospects of depressed patients who are refractory to current approaches.

Full Text available with Trip Pro

2017 Psychological Medicine

18. Transcranial Magnetic Stimulation for Major Depression and Schizophrenia

two different classes of antipsychotic drugs given for a minimum of four weeks. TRANSCRANIAL MAGNETIC STIMULATION FOR MAJOR DEPRESSION AND SCHIZOPHRENIA | SAX INSTITUTE 7 Preface The Report on evidence for Transcranial Magnetic Stimulation for Major Depression and Schizophrenia (the Report) has been commissioned by the NSW Ministry of Health as a nomination of the NSW new health technology evaluation program. A project management group (PMG), including the NSW Health Chief Psychiatrist, key (...) of emotions via facial expression or voice tone), reduced feelings of pleasure in everyday life, difficulty beginning and sustaining activities and diminished speaking. Cognitive symptoms arise as a result of deficits in memory, attention and learning ability. As with depression, schizophrenia is diagnosed based on DSM-V and ICD-10 criteria. Management For the management of depression during initial depressive episodes patients receive pharmacotherapy and psychosocial therapy based on severity of symptoms

2018 Sax Institute Evidence Check

19. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: major depression summary

personalised care to the individual, and delivering care in the context of a therapeutic relationship. In practice, the management of depression is determined by a multitude of factors, including illness severity and putative aetiology, with the principal objectives of regaining premorbid functioning and improving resilience against recurrence of future episodes. Main recommendations: The guidelines emphasise a biopsychosocial lifestyle approach and provide the following specific clinical recommendations (...) : Alongside or before prescribing any form of treatment, consideration should be given to the implementation of strategies to manage stress, ensure appropriate sleep hygiene and enable uptake of healthy lifestyle changes. For mild to moderate depression, psychological management alone is an appropriate first line treatment, especially early in the course of illness. For moderate to severe depression, pharmacological management is usually necessary and is recommended first line, ideally in conjunction

2018 MJA Clinical Guidelines

20. Esketamine for Treatment-Resistant Depression

duration of esketamine treatment and whether it can eventually be tapered or discontinued. Furthermore, there is a lack of evidence comparing intranasal esketamine to current adjunctive strategies for TRD. References Lam RW, McIntosh D, Wang J, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 1. disease burden and principles of care. Can J Psychiatry. 2016;61(9):510-523. Depression and other (...) guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments. Can J Psychiatry. 2016;61(9):540-560. Ketamine for treatment-resistant depression or post-traumatic stress disorder in various settings: a review of clinical effectiveness, safety, and guidelines. (CADTH Rapid response report: summary with critical appraisal) . Ottawa (ON): CADTH; 2017: . Accessed 2019 Jan 28. Serafini G, Howland RH, Rovedi F, Girardi P, Amore M. The role of ketamine

2019 CADTH - Issues in Emerging Health Technologies

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>